Andrew Roberts leads portfolio strategy for Alvotech’s selection of pipeline assets, including overseeing several enterprise leadership functions responsible for the successful registration and partner commercialization of our biosimilars. He brings with him significant strategy experience, contributing to both originator and biosimilar strategy and development over his 18-year career in the pharmaceutical industry.
Most recently, Andrew was Senior Global Program Head for Sandoz, a division of Novartis, and led both development portfolio strategy as well as the completion of several key collaboration agreements for Sandoz's biosimilar portfolio. Prior to that role, Andrew held additional leadership positions at Novartis in charge of originator development teams in a variety of therapeutic areas and worked on portfolio strategy at the group level for the Board of Directors. He rounds out his pharmaceutical industry experience at Biogen Idec.
Andrew holds an Executive MBA from INSEAD, a Master of Science in Nutrition and a Bachelor of Science in Biology from Louisiana State University.